ClinicalTrials.gg
CompletedNCT05614115Updated Oct 30, 2026Results posted

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

A Phase 1 interventional study of Empagliflozin and Placebo in End-stage Kidney Disease, Kidney Disease, Chronic and Dialysis, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of Utah · Phase 1, Interventional, and Treatment

How we know

Updated Oct 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
268th of 638
62 · median 48
Started
2023
with 29 others
Phase 1
89 of 765
8 open now
Registered
679th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 268th largest by enrollment of the 638 interventional ones that give a count, is one of 30 that started in 2023, is one of 89 in phase 1, and was the 679th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients. In the recent years, empagliflozin has become a major tool to prevent heart failure hospitalization and to reduce the risk for cardiovascular death in diabetic and non-diabetic patients. Although patients with severe chronic kidney disease and ESKD have very high risk of heart failure and cardiovascular death, they have been excluded from all of the previous studies. If this medication is found to be well tolerated and safe in dialysis patients through this study, future clinical studies can evaluate if this medication can also reduce the risk of heart failure and cardiovascular death in dialysis patients.

Read the detailed description

Patients on dialysis have a very high risk of heart failure and heart-related death compared to people who do not require dialysis. While treatment options for heart failure have improved over the years for those without kidney disease, there has been very limited discoveries to improve survival for dialysis patients.

Empagliflozin, a new diabetic medication that works by making the kidney put out more sugar in the urine, has recently shown to have significant efficacy to protect the kidney and to reduce heart failure hospitalization and cardiovascular death in both diabetic and non-diabetic patients. Studies suggest that this medication may have benefits on the heart, fat cells, blood vessels, and possibly other organ systems. The benefit remains consistent whether you have diabetes or not. Empagliflozin is now approved by the U.S. Food and Drug Administration (FDA) to treat not only diabetes but also chronic kidney disease and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults regardless of the diabetes status.

The clinical studies, however, have excluded those with severe kidney disease and those requiring dialysis. The safety of empagliflozin in the dialysis patients has not been established, and thus it is not available for people with end-stage kidney disease. If empagliflozin is safe in dialysis patients, it may potentially become a very powerful tool to lower the risk of heart-related complications and prolong survival.

Although empagliflozin is approved by the FDA to treat patients with chronic kidney disease, heart failure, and/or diabetes, our study will evaluate empagliflozin as an investigational drug to assess if it is safe in patients receiving chronic dialysis. If we can establish safety, the next step would be to conduct a larger clinical study to evaluate its ability to lower heart failure and death risk in dialysis patients.

03

Conditions studied

  • End-stage Kidney Disease
  • Kidney Disease, Chronic
  • Dialysis
  • Diabetic
  • Non-diabetic
  • Kidney Dysfunction
  • Kidney Failure
  • Hemodialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • include diabetic and non-diabetic adults
  • dialysis treatment history of ≥3 months

Exclusion criteria

Exclusion Criteria:

  • type 1 diabetes
  • ongoing intravenous antibiotic therapy for infectious disease
  • active treatment for
  • unhealed lower extremity skin ulceration
  • history of Fournier's gangrene
  • diabetic ketoacidosis
  • severe hypoglycemia (requiring external assistance within the past one year)
  • allergy to empagliflozin
  • pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Empagliflozin 10mg

    Empagliflozin10mg oral: Those randomized to 10 mg daily dose will be treated with 10 mg QD throughout the dose escalation and the treatment phase for a total of 12 weeks.

    Drug: Empagliflozin

  • Experimental
    Empagliflozin 25mg

    Empagliflozin 25 mg oral: Those randomized to 25 mg daily dose will be treated with 10 mg QD for the first 2 weeks before escalating the dose to 25 mg QD in week 3, based on tolerability. At the end of the dose-escalation phase (weeks 3-4), participants will continue the randomized assignment for additional 8 weeks (weeks 5-12, treatment phase), for a total of 12 weeks.

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Encapsulated placebo with an identical appearance to empagliflozin: Those randomized to placebo will be treated with an oral placebo QD throughout the dose escalation and the treatment phase for a total of 12 weeks.

    Other: Placebo

Interventions

  • is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

    Also known as: Jardiance®, CL-JAR-100113 02.28.2022

  • OtherPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Study Completion

    The number of participants in each intervention group who remain in follow-up and adhere to the full randomized dose of empagliflozin and placebo at the end of the 12-week intervention period.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Participants in Each Group Who Reduce and/or Discontinue Treatment for Safety

    Number of participants in each group who reduce and/or discontinue treatment due to safety events.

    Time frame: 12-weeks

  2. Tolerance to Study Treatment

    Number of participants in each group who reduce and/or discontinue treatment because of intolerance (i.e., allergy, nausea) or other reasons unrelated to safety (i.e., pill burden, study withdrawal due to transplant)

    Time frame: 12-weeks

  3. Study Drug Compliance by Bottle Count

    Number of study drug bottles returned by subjects

    Time frame: 12-weeks

  4. Dialytic Clearance of Empagliflozin

    Percentage of empagliflozin removed by a 4-hour dialysis treatment

    Time frame: 4 hours post-dose during hemodialysis

  5. Long-term Accumulation of Empagliflozin

    Empagliflozin plasma concentration after 10 weeks of dosing

    Time frame: 10 weeks

07

Results

Posted Oct 30, 2026

Participant flow

Dose Escalation Phase (Weeks 1-4)
Participant flow — Dose Escalation Phase (Weeks 1-4)
MilestoneEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Started222020
Completed201717
Not completed233
Treatment Phase (Weeks 5-12)
Participant flow — Treatment Phase (Weeks 5-12)
MilestoneEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Started201717
Completed181216
Not completed251

Outcome measures

PrimaryStudy Completion

The number of participants in each intervention group who remain in follow-up and adhere to the full randomized dose of empagliflozin and placebo at the end of the 12-week intervention period.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Study Completion
ParticipantsEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Study Completion181216
SecondaryNumber of Participants in Each Group Who Reduce and/or Discontinue Treatment for Safety

Number of participants in each group who reduce and/or discontinue treatment due to safety events.

Time frame:
12-weeks
Reported as:
Count of participants · Participants
Number of Participants in Each Group Who Reduce and/or Discontinue Treatment for Safety
ParticipantsEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Number of Participants in Each Group Who Reduce and/or Discontinue Treatment for Safety101
SecondaryTolerance to Study Treatment

Number of participants in each group who reduce and/or discontinue treatment because of intolerance (i.e., allergy, nausea) or other reasons unrelated to safety (i.e., pill burden, study withdrawal due to transplant)

Time frame:
12-weeks
Reported as:
Count of participants · Participants
Tolerance to Study Treatment
ParticipantsEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Tolerance to Study Treatment010
SecondaryStudy Drug Compliance by Bottle Count

Number of study drug bottles returned by subjects

Time frame:
12-weeks
Reported as:
Number · number of drug bottles returned
Study Drug Compliance by Bottle Count
number of drug bottles returnedEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Study Drug Compliance by Bottle Count716270
SecondaryDialytic Clearance of Empagliflozin

Percentage of empagliflozin removed by a 4-hour dialysis treatment

Time frame:
4 hours post-dose during hemodialysis
Reported as:
Mean · Percent of drug removed by dialysis
Dialytic Clearance of Empagliflozin
Percent of drug removed by dialysisEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Dialytic Clearance of Empagliflozin17.0 (15.1 to 18.9)7.4 (5.9 to 8.8)—
SecondaryLong-term Accumulation of Empagliflozin

Empagliflozin plasma concentration after 10 weeks of dosing

Time frame:
10 weeks
Reported as:
Median · ng/mL
Long-term Accumulation of Empagliflozin
ng/mLEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Long-term Accumulation of Empagliflozin39.1 (10.6 to 188.0)55.8 (1.5 to 131.0)—

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empagliflozin 10mg0/22 (0%)5/22 (22.7%)5/22 (22.7%)
Empagliflozin 25mg2/20 (10%)8/20 (40%)9/20 (45%)
Placebo0/20 (0%)6/20 (30%)7/20 (35%)
Most frequent serious events
Most frequent serious events
EventEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/221/202/20
HypervolemiaCardiac disorders1/222/201/20
Infection/SepsisInfections and infestations1/221/202/20
Non-ST-Segment Elevation Myocardial InfarctionCardiac disorders1/221/200/20
HypoglycemiaEndocrine disorders0/220/201/20
Bone FractureMusculoskeletal and connective tissue disorders0/221/200/20
EmesisGastrointestinal disorders0/221/200/20
DepressionPsychiatric disorders0/221/200/20
Most frequent other events
Most frequent other events
EventEmpagliflozin 10mgEmpagliflozin 25mgPlacebo
DiarrheaGastrointestinal disorders3/226/206/20
Urinary Tract InfectionRenal and urinary disorders1/221/200/20
ConfusionPsychiatric disorders0/221/201/20
HypoxiaRespiratory, thoracic and mediastinal disorders1/221/200/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
Mean61.6 ± 17.5857.6 ± 10.1855.6 ± 10.1258.3 ± 13.31
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
Female66820
Male16141242
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
Hispanic or Latino48921
Not Hispanic or Latino18121141
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
American Indian or Alaska Native0213
Asian0000
Native Hawaiian or Other Pacific Islander3418
Black or African American2103
White1691742
More than one race0000
Unknown or Not Reported1416
Region of Enrollment
Region of Enrollment(participants)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
United States22202062
BMI
BMI(kg/m^2)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
Mean32.2 ± 5.0229.3 ± 6.0432.2 ± 8.2031.3 ± 6.55
Type 2 diabetes
Type 2 diabetes(Participants)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
Count of participants14151443
Heart failure
Heart failure(Participants)Empagliflozin 10mgEmpagliflozin 25mgPlaceboTotal
Count of participants118524
08

Study locations

1 site
  • University of Utah
    Salt Lake City, Utah 84132, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jun 2025, 27 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 67 phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 14, 2022
StartActual
Mar 21, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore The proportion of participants in each intervention group who remain in follow-up and adhere to the full randomized dose of empagliflozin at the end of the 12-week intervention period.Now Study CompletionTime frame: 12 weeks
Oct 30, 2026
Secondary outcomes
3 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedProportionsNumber of participantsParticipants in each group who reduceEach Group Who Reduce and/or discontinue treatmentDiscontinue Treatment for safetySafetyTime frame: 12-weeks
  • EditedDialytic clearanceClearance of empagliflozinEmpagliflozinTime frame: 4 hours post-dose during hemodialysis
  • EditedLong-term accumulationAccumulation of empagliflozinEmpagliflozinTime frame: 10 weeks
  • AddedTolerance to Study TreatmentTime frame: 12-weeks
  • AddedStudy Drug Compliance by Bottle CountTime frame: 12-weeks
  • RemovedProportions of participants in each group who reduce and/or discontinue treatment because of intolerance (i.e., allergy, nausea) or other reasons unrelated to safety (i.e., pill burden, study withdrawal due to transplant)Time frame: 12-weeks
  • RemovedProportions of participants in each group who have ≥ 80% pill count compliance.Time frame: 12-weeks
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore The proportion of participants in each intervention group who remain in follow-up and adhere to the full randomized dose of empagliflozin at the end of the 12-week intervention period.Now Study CompletionTime frame: 12 weeks
    Secondary outcomes 3 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedProportionsNumber of participantsParticipants in each group who reduceEach Group Who Reduce and/or discontinue treatmentDiscontinue Treatment for safetySafetyTime frame: 12-weeks
    • EditedDialytic clearanceClearance of empagliflozinEmpagliflozinTime frame: 4 hours post-dose during hemodialysis
    • EditedLong-term accumulationAccumulation of empagliflozinEmpagliflozinTime frame: 10 weeks
    • AddedTolerance to Study TreatmentTime frame: 12-weeks
    • AddedStudy Drug Compliance by Bottle CountTime frame: 12-weeks
    • RemovedProportions of participants in each group who reduce and/or discontinue treatment because of intolerance (i.e., allergy, nausea) or other reasons unrelated to safety (i.e., pill burden, study withdrawal due to transplant)Time frame: 12-weeks
    • RemovedProportions of participants in each group who have ≥ 80% pill count compliance.Time frame: 12-weeks
    + 4 other changes: index terms, verification date, data sharing statement and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05614115
Lead sponsor
University of Utah
Responsible party
Monique Cho (Associate Professor in the Department of Medicine, Division of Nephrology & Hypertension, University of Utah) — Principal investigator
First posted
Nov 14, 2022
Start date
Mar 21, 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion